Key result
Dexamethasone administration was temporally associated with the onset of Takotsubo cardiomyopathy in a patient with immune thrombocytopenic purpura.
Why the study?
To highlight pharmacologic agents such as dexamethasone as potential non-traditional triggers of Takotsubo cardiomyopathy in patients without identifiable emotional or physical stressors.
Case Report (n=1)
Pharmacologic agents such as dexamethasone should be recognized as potential non-traditional triggers for Takotsubo cardiomyopathy, especially in patients with underlying cardiovascular disease.
May prompt consideration of dexamethasone as a non-traditional trigger in unexplained Takotsubo cases; leaves open causal confirmation beyond this single report.
This case report highlights a temporal relationship between dexamethasone administration and the onset of Takotsubo cardiomyopathy, underscoring the importance of recognizing pharmacologic agents as potential non-traditional triggers, particularly in patients with underlying cardiovascular disease and no identifiable emotional or physical stressors. Diagnosis favored a dexamethasone-triggered Takotsubo phenotype based on non-obstructive coronaries, regional wall-motion abnormalities extending beyond a single arterial territory, absence of alternate stressors, and biologic plausibility of steroid-mediated catecholaminergic upregulation.
No takes yet. Share an insight, caveat, or question.
Qafisheh et al. (2025) conducted a case report in Immune Thrombocytopenic Purpura and Takotsubo Cardiomyopathy (n=1). Dexamethasone was evaluated on Onset of Takotsubo cardiomyopathy. Dexamethasone administration was temporally associated with the onset of Takotsubo cardiomyopathy in a patient with immune thrombocytopenic purpura.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: